HeimBMY • NYSE
add
Bristol-Myers Squibb Co
Við síðustu lokun
45,61 $
Dagbil
45,43 $ - 46,51 $
Árabil
42,52 $ - 63,33 $
Markaðsvirði
92,67 ma. USD
Meðalmagn
18,65 m.
V/H-hlutf.
15,39
A/V-hlutfall
5,44%
Aðalkauphöll
NYSE
Í fréttum
Fjármál
Rekstrarreikningur
Tekjur
Nettótekjur
| (USD) | sep. 2025info | Breyting á/á |
|---|---|---|
Tekjur | 12,22 ma. | 2,77% |
Rekstrarkostnaður | 5,05 ma. | -26,13% |
Nettótekjur | 2,20 ma. | 81,75% |
Hagnaðarhlutfall | 18,01 | 76,92% |
Hagnaður á hvern hlut | 1,63 | -9,44% |
EBITDA | 4,91 ma. | 1,38% |
Virkt skatthlutfall | 29,51% | — |
Efnahagsreikningur
Heildareignir
Heildarskuldir
| (USD) | sep. 2025info | Breyting á/á |
|---|---|---|
Reiðufé og skammtímafjárfestingar | 16,50 ma. | 103,88% |
Heildareignir | 96,89 ma. | 3,44% |
Heildarskuldir | 78,29 ma. | 2,38% |
Eigið fé alls | 18,60 ma. | — |
Útistandandi hlutabréf | 2,04 ma. | — |
Eiginfjárgengi | 5,01 | — |
Arðsemi eigna | 10,07% | — |
Ávöxtun eigin fjár | 13,97% | — |
Peningaflæði
Breyting á handbæru fé
| (USD) | sep. 2025info | Breyting á/á |
|---|---|---|
Nettótekjur | 2,20 ma. | 81,75% |
Handbært fé frá rekstri | 6,31 ma. | 12,88% |
Reiðufé frá fjárfestingum | -1,70 ma. | -677,17% |
Reiðufé frá fjármögnun | -1,49 ma. | 61,32% |
Breyting á handbæru fé | 3,12 ma. | 95,05% |
Frjálst peningaflæði | 4,26 ma. | -23,81% |
Um
Bristol-Myers Squibb Company is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are Apixaban for people with atrial fibrillation; nivolumab, used to treat certain types of cancer; lenalidomide, used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes; abatacept, used to treat autoimmune diseases such as rheumatoid arthritis; pomalidomide, an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma; ipilimumab, to treat cancer; and luspatercept for the treatment of anemia in beta thalassemia and myelodysplastic syndromes. In 2024, 71% of the company's revenues came from the United States.
The company is ranked 94th on the Fortune 500 and 173rd on the Forbes Global 2000.
BMS's primary research and development sites are located in Lawrence, New Jersey, Summit, New Jersey, formerly HQ of Celgene, New Brunswick, New Jersey; Redwood City, California; and Seville in Spain, with other sites in Devens and Cambridge, Massachusetts; Braine-l'Alleud, Belgium; Tokyo, Japan; Hyderabad; Bangalore, India and Wirral, United Kingdom. Wikipedia
Framkvæmdastjóri
Stofnsett
1887
Höfuðstöðvar
Vefsvæði
Starfsfólk
34.100
